Macrovascular

Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Bedenis R, Price AH, Robertson CM, et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2014. [ePub ahead of print] doi: 10.2337/dc14-0908.

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes

Top

Neugebauer R, Fireman B, Roy JA, O’Connor PJ. Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. Diabetes Care. 2013;36:3510-3516.

Changes in diabetes-related complications in the United States, 1990–2010

Top

Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514-1523.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Top

Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention with Exenatide Once-Weekly) is a series of multinational studies comparing once-weekly exenatide with other antihyperglycemic therapies for treatment of type 2 diabetes.

Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy.

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of ADVANCE. Morton J, Zoungas S, Li Q, et al; on behalf of the ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy. Diabetes Care. 2012;35:2201-2206. Macro- and microvascular complications remain significant concerns in the treatment of patients with type 2 diabetes.

Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT).

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of VADT. Saremi A, Bahn G, Reaven PD; for the VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390-2392. Cross-sectional data from the Veterans Affairs Diabetes Trial (VADT) showed that participants with coronary artery or abdominal aortic calcification had an increased prevalence of cardiovascular disease, including peripheral artery disease and coronary artery disease.

Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes.

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of SOS. Romeo S, Maglio C, Burza CA, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care. 2012;32:2613-2617. The Swedish Obese Subjects (SOS) study is a nonrandomized, controlled, prospective interventional trial that compares the effects of bariatric surgery and usual care on morbidity and mortality outcomes.

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

1 2 3 4 5 6 7 8 9 10  ... Next